OncoMatch/Clinical Trials/NCT06444269
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
Is NCT06444269 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies microbubble CEUS Contrast Enhanced Ultrasound (CEUS) for breast cancer.
Treatment: microbubble CEUS Contrast Enhanced Ultrasound (CEUS) — 1\. Efficacy of PULSAR preoperative radiation 2. Evaluate potential of microbubble CEUS as an alternative to operative SLNBx 3. Evaluate potential of OA to evaluate treatment response of pre-operative radiation on the tumor
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
Required: ESR1 positive
Required: PR (PGR) positive
Prior therapy
Cannot have received: radiation therapy
Prior Radiation to the involved breast
Cannot have received: endocrine therapy
have not undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer diagnosis
Cannot have received: chemotherapy
have not undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer diagnosis
Cannot have received: surgery
have not undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer diagnosis
Cannot have received: any therapy for ipsilateral breast cancer
Prior ipsilateral breast cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center-Dallas · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify